Overview of Hemo 15

Property	Description
Active Ingredient	Multivitamin, Amino acid, and Mineral complex (e.g., Cyanocobalamin, Ferric ammonium citrate)
Form	Sterile solution for injection
Pharmacological Class	Hematinic and General Reconstituent Agent
General Purpose	Nutritional support to counter deficiencies and support vitality
Origin	Synthetic Combination Product

Hemo 15 is a complex veterinary pharmaceutical preparation formulated as a sterile solution for injection, distinguishing it from oral supplements due to its parenteral route of administration. The product is categorized as a multivitamin, multimineral, and amino acid supplement, placing it within the pharmacological class of hematinics and general reconstituent agents. This synthetic combination product uniquely blends over fifteen active components, a feature often clinically recognized for maximizing bioavailability compared to oral alternatives.

Core Composition and Identity-Level Ingredients

The preparation’s core composition focuses on essential blood-forming nutrients. It includes key B-complex vitamins—such as Cyanocobalamin (Vitamin B12), which is vital for erythropoiesis—trace minerals (e.g., Iron from Ferric ammonium citrate, Copper, and Cobalt), and essential amino acids (like DL-methionine and DL-lysine). The combination of iron and Vitamin B12 is recognized for its role in supporting nutritional status. The complexity of the formula ensures multiple metabolic pathways are supported simultaneously.

General Therapeutic Purpose

The general purpose of Hemo 15 is to act as a nutritional restorative agent intended to help counter deficiencies in vital blood-forming nutrients and metabolic co-factors. By supplying these high-demand components in an injectable form, the preparation is designed to help maintain vitality and supports recovery during periods of high physiological demand or nutrient depletion, fulfilling its established role as a general reconstituent.

What side effects are possible with Hemo 15?

Possible Side Effects and Safety Information

The safety profile for Hemo 15 is defined primarily by its official regulatory status rather than a standard, approved list of clinical adverse reactions. The product lacks an approved safety label that provides specific details on adverse event frequencies, such as Common, Uncommon, or Rare, as required by major governmental health authorities (FDA, EMA) for approved medications.

Regulatory Status and High-Level Safety Constraints

The most significant safety consideration documented in government-backed regulatory texts is the product’s status as an unapproved compounded drug. In the United States, injectable compounded preparations of this type are regulated by the Food and Drug Administration (FDA) as unapproved animal drugs. This status signifies that the substance has not undergone the formal regulatory review process necessary to certify its safety and efficacy.

Classification as Banned Substance: Certain government-backed regulatory bodies, such as the Horseracing Integrity & Welfare Unit (HIWU), classify Hemo 15 as an S0 Non-Approved Banned Substance.
Population-Specific Prohibition: The use of the substance is explicitly prohibited within regulated populations, such as a Covered Horse, establishing a definitive regulatory safety restriction for this group.

Adverse Reaction Documentation

Adverse Reaction Scope	Regulatory Documentation Status
Frequency Categories (Common, Rare, etc.)	Not documented in an approved regulatory safety label.
System-Organ Classes (Gastrointestinal, etc.)	Not defined by regulatory authorities due to non-approved status.
Serious Adverse Reactions	Concern is focused on risks associated with unapproved injectable products lacking formal safety review.

Its use is subject to Federal law restrictions and is considered non-compliant with standard regulatory acts concerning approved substances, making the regulatory constraints themselves the defining safety characteristic.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with this multivitamin and mineral complex is primarily defined by the severe toxicity risk associated with its iron component. The official regulatory profile notes that initial presentations commonly involve pronounced gastrointestinal symptoms, including severe nausea, protracted vomiting, diarrhea, and intense abdominal pain.

Official Manifestations and Progression

Regulatory documents note that overdose may rapidly progress beyond these initial signs to life-threatening systemic outcomes. These severe outcomes include metabolic acidosis, circulatory shock, hepatic necrosis (liver damage), and eventual cardiovascular collapse. These risks are the basis for the strict regulatory requirement for intervention.

Mandatory Emergency Action and Management

Due to the potential for sequential symptom manifestation, government regulatory guidance strictly mandates that individuals seek immediate medical attention for any suspected overdose event. It is explicitly required to contact emergency services immediately or the nearest Poison Control Center.

Management involves symptomatic and supportive treatment and may require specific procedural interventions documented in the official label, such as chelation therapy and whole bowel irrigation to limit absorption. Continuous hospital monitoring is mandatory, including serial monitoring of serum iron concentrations and continuous observation. Official labeling notes increased susceptibility and severity in the pediatric population and in those with existing hepatic impairment.

Therapeutic Uses of Hemo 15

What Hemo 15 Treats: Main Uses and Benefits

Hemo 15 is generally considered relevant in situations involving symptomatic discomfort and is commonly used to help manage symptom clusters related to systemic imbalance.

Its classification as a hematinic complex indicates relevance for symptomatic support in these systemic issues.

This supportive care is commonly used to help with symptoms associated with conditions marked by increased physiological stress, including manifestations related to nutritional anemia, post-illness convalescence, and high-demand phases like intensive training or lactation. It is commonly used when symptoms appear suddenly or fluctuate due to temporary physiological imbalance.

“The primary benefit is that it supports general well-being during symptomatic phases and may help patients cope more steadily with difficult episodes.”

Quick Fact: Relief for Systemic Weakness

Hemo 15 is relevant for easing symptoms related to systemic imbalance, such as generalized lethargy, chronic weakness, and easy fatigability, which are common manifestations of these nutritional gaps. This contributes to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Eligibility for Hemo 15: Official Regulatory Status

The eligibility for Hemo 15 is strictly defined by its regulatory classification as a veterinary pharmaceutical product, which establishes clear boundaries for use.

Classification	Eligible Population	Contraindicated Population
Approved Species	Cattle, Swine, Horses	Humans (Use is not authorized)
Use Restriction	General Veterinary Use	Covered Horses in Regulated Racing

The most fundamental rule is the absolute contraindication for human use, as the product is not approved by major governmental health regulatory authorities for human consumption or therapeutic purposes. Use is formally permitted only in specific animal species, including Cattle, Swine, and Horses, as listed in regulatory documents.

Use in horses is subject to specific regulatory limits: Hemo 15 is classified as an S0 Non-Approved Banned Substance and is prohibited from use at all times in Covered Horses under the anti-doping regulations of regulated US racing. Official labels do not typically specify restrictions related to age, pregnancy, lactation, or organ function within the approved animal species.

What should I know about interactions with other medicines?

The interaction profile for this multi-component preparation is derived from the mandated regulatory warnings associated with its essential active components, primarily Cyanocobalamin (Vitamin B12) and trace minerals. The officially documented interaction information focuses on strict prohibitions and potential changes to component efficacy.

Formal Prohibitions and Restrictions

Co-administration of the Cyanocobalamin component is formally restricted in specific patient populations. It is documented as contraindicated in individuals diagnosed with Leber's Hereditary Optic Atrophy due to the risk of severe optic nerve damage. Use is also formally prohibited in individuals with a known history of sensitivity or hypersensitivity to Cobalt or Vitamin B12.

Pharmacodynamic and Efficacy Interactions

Certain medicinal products can alter the availability or therapeutic outcome of Hemo 15 components. The antibiotic Chloramphenicol may reduce the expected hematopoietic (blood-forming) response to the Cyanocobalamin component. Additionally, the co-administration of high-dose Folic Acid is officially documented to potentially obscure the hematological signs of an underlying B12 deficiency, which carries a risk of allowing progressive neurological damage to occur.

Interactions with Supplements and Organ Function

High-dose Ascorbic Acid (Vitamin C) supplements may lower the total available amount of B12 within the body. A population-specific constraint is noted concerning the injectable formulation's trace Aluminum content. Prolonged parenteral use of aluminum-containing solutions carries an accumulation risk that can lead to toxicity, requiring particular caution in patients with impaired kidney function (renal impairment).

Mechanism of Action

Mechanism of Action: Cofactor Integration in Hemopoietic Pathways

The function of this formulation is based on providing essential mineral and vitamin cofactors required for cellular metabolism, primarily targeting the Erythropoiesis cascade (red blood cell production). The mechanism involves the presence of Cobalt, which can act as a signaling modulator by potentially supporting the Hypoxia-Inducible Factor (HIF) pathway that governs Erythropoietin production. This influences the signaling required for hematopoietic progenitor cell differentiation.

Simultaneously, the B-vitamin complex serves as coenzymes within critical metabolic pathways, including the Krebs cycle and one-carbon metabolism. This facilitates the high metabolic flux and proliferation rates characteristic of rapidly dividing hematopoietic cells, supporting DNA synthesis and repair via B12 and Folic Acid. Furthermore, Iron and Copper engage in a mechanistic interaction: Copper is a necessary cofactor for key ferroxidases that mediate the mobilization and efficient incorporation of Iron into the developing red blood cell for Heme assembly, which is structurally integral to oxygen-binding function.

Dosage and Administration Information

How to use Hemo 15: Official Administration Guidelines

Hemo 15 is a veterinary medicinal product authorized for administration solely to horses, cattle, and swine. The official instructions for its use detail a specific procedural structure focused on the route, dose, and frequency of injection.

Administration Scope

The product is an injectable solution approved for use via Intramuscular (IM) or Intravenous (IV) routes only. The dose is calculated based on body weight:

Species	Dose	Frequency	Duration
Horses, Cattle, Swine	1 mL per 45 kg body weight per day	Every second day	One week to 10 days (4 to 5 total administrations)

Official Procedural Steps

Preparation: Ensure strict sterile techniques are maintained during the preparation and administration of the injectable solution, as required for all injectable veterinary products.
Dosing: Calculate the exact volume of Hemo 15 based on the animal's weight, adhering to the mandated ratio of 1 mL per 45 kg body weight.
Administration: Administer the calculated dose via the specified Intramuscular or Intravenous route.
Repeat Schedule: The administration is to be repeated every second day for the full course of treatment.
Monitoring: The official instructions mandate that if no improvement is observed after a 7- to 10-day period, a veterinarian must be consulted to discontinue or re-evaluate the treatment plan.

Regulatory Summary

The protocol is classified as an injectable method with a set, intermittent frequency (every second day) over a limited duration. Its regulatory basis is derived from veterinary marketing authorizations for specific species. The use is contextually constrained solely to the authorized animal species.

Recent Clinical Evidence

Regulatory Status and Clinical Data

Hemo 15 is a compounded injectable solution containing a mixture of B-vitamins, amino acids, and minerals such as iron and cobalt. It is typically marketed and used as a hematinic agent to support the formation of red blood cells. It is important to note that Hemo 15 is not an approved drug by major regulatory bodies such as the U.S. Food and Drug Administration (FDA) for human use.

Evidence of Efficacy in Clinical Settings

Scientific literature does not contain published, peer-reviewed human clinical trials (such as Phase 3 randomized controlled trials) that definitively assess the safety and efficacy of the Hemo 15 formulation for treating anemia or other blood-related conditions in humans. The product's intended function is based on the known physiological roles of its individual components (e.g., Vitamin B12 and iron are essential for erythropoiesis, the process of making red blood cells).

Iron: The inclusion of iron (such as Ferric ammonium citrate) is intended to provide a necessary component for hemoglobin synthesis and oxygen transport.
Cobalt: The concentration of cobalt gluconate is noteworthy, as cobalt ions have been observed in research settings to stimulate the production of erythropoietin (EPO), a hormone that promotes red blood cell formation. This effect is not a confirmed therapeutic mechanism for the final compounded product in human medicine.

Due to the lack of regulatory approval and the absence of high-quality human clinical data, Hemo 15 cannot be classified as an evidence-based medical treatment. Any use of this formulation is considered off-label in the absence of a confirmed medical indication or safety profile supported by regulatory review.

Key Studies & References

Cobalt Exposure and Health Effects - Summary of Hematologic Effects

Frequently Asked Questions (FAQ)

Common questions about Hemo 15 (FAQ)

Q: What is the main reason doctors prescribe Hemo 15?

According to official product documentation, Hemo 15 is a veterinary medicinal product indicated for use in approved species, such as horses, cattle, and swine. It is used as a nutritional supplement to help counter deficiencies in vital blood-forming nutrients and metabolic cofactors. Its purpose is to support the animals' vitality, particularly during periods of high physiological demand.

Q: Is Hemo 15 a type of blood thinner?

No, Hemo 15 is not classified as a blood thinner. Official documentation categorizes the product as a hematinic and a general reconstituent agent. This means its documented function is to support the formation of blood components, such as red blood cells.

Q: Can Hemo 15 cause stomach upset or nausea?

The product lacks an approved human safety label, and its administration as an injection to animals bypasses the gastrointestinal tract. Its components, such as Iron, are noted in general regulatory contexts to be associated with gastrointestinal discomfort. The official regulatory status makes it impossible to provide a definitive frequency or likelihood of this reaction.

Q: Are there any common foods or drinks to avoid while using Hemo 15?

The official veterinary labeling for Hemo 15 does not typically list specific food or drink interactions. Since the product is an injectable solution, human-specific dietary guidance is not provided due to the product’s veterinary classification.

Q: Is Hemo 15 safe for people with a history of liver issues?

Hemo 15 is explicitly classified as an unapproved animal drug by major government health authorities. Because the product is not authorized for human use, regulatory bodies have not certified its safety or eligibility for human populations with liver issues.

Q: Can older adults use Hemo 15 safely?

Hemo 15 is not approved for human consumption or therapeutic purposes. Consequently, official safety guidelines regarding its use in any human population, including older adults, are not available.

Q: Can Hemo 15 be used by people who are vegetarian or vegan?

The product is a compounded injectable solution for veterinary use only and is not authorized for humans. Regulatory documentation focuses on chemical composition and safety for the approved species, rather than ingredient origin certifications relevant to human dietary choices.

Q: What is the recommended period of time for using Hemo 15?

The official administration guidelines, which apply to the approved animal species, specify that Hemo 15 is intended for a limited, short course of treatment. The documented duration is typically for a period of one week to 10 days.

Q: What if I experience a rash after starting Hemo 15?

The official product monograph for Hemo 15 in its approved species notes that known sensitivity or hypersensitivity to components like Cobalt or Vitamin B12 is a formal prohibition for its use. Hypersensitivity reactions are a required reporting area in official safety documentation.

Q: Is Hemo 15 ever used for energy or fatigue?

Its official purpose, based on its components, is described as acting as a nutritional restorative agent intended to support general vitality during times of high physiological demand in the approved animal species. This is the documented intent related to general health support.

Q: Are there official restrictions on driving while using Hemo 15?

Since Hemo 15 is not an approved human medication, official regulatory guidance concerning human activities like driving is not established. Restrictions on activities are only provided for products authorized for human use.

Q: Can Hemo 15 interact with herbal supplements like St. John's Wort?

Official product information would list known drug interactions. Because Hemo 15 is not an approved human drug, specific data concerning non-approved supplements like St. John’s Wort may not be available in regulatory documentation for this product.

Q: Is Hemo 15 a long-term treatment or a short course?

Based on the official administration guidelines for the approved animal species, Hemo 15 is administered over a limited duration (one week to 10 days), classifying it as a short course of treatment.

Q: Can people with kidney problems use Hemo 15?

Hemo 15 is not authorized for human use by government health authorities. Consequently, official safety guidance for human populations with kidney impairment is not available.

Q: What are the potential signs of using too much Hemo 15?

The official product monograph for Hemo 15 for the approved animal species includes information in the Overdose section. This section details the potential signs observed in the approved animal species in case of excessive use, focusing on the veterinary context.

Q: Has Hemo 15 been recalled or subject to any major safety warnings recently?

Government regulatory agencies maintain official product databases that document all regulatory actions. Any official reports regarding recalls, market withdrawals, or major safety warnings for Hemo 15 would be recorded and made public by these authorities.

Q: Is there a generic version of Hemo 15 available?

Regulatory product databases track drug approvals, including generic versions. The status of generic availability for Hemo 15 is determined by its regulatory classification as a compounded or approved product in each jurisdiction.

Q: Is Hemo 15 commonly misunderstood by patients or the public?

Hemo 15's official regulatory classification as an unapproved animal drug and its designation as an S0 Non-Approved Banned Substance in certain regulated populations indicates that its intended use and approval status may be frequently mistaken or misinterpreted by the general public.

Q: Does using Hemo 15 require any dietary changes?

As Hemo 15 is an injectable veterinary solution, the regulatory labeling does not typically include instructions regarding dietary changes. Such guidance is primarily provided for orally administered medications where food interactions are a factor.

Q: Can Hemo 15 make certain medical tests inaccurate?

Official product monographs typically contain a dedicated section on Drug-Laboratory Test Interactions. This section details any documented effects of Hemo 15 components on laboratory results in the approved species.

Q: Is Hemo 15 the same as the drug 'Product X' I saw advertised?

Hemo 15 is officially defined as a synthetic combination product, containing a specific mixture of multiple ingredients, including vitamins, amino acids, and minerals. Its official classification is based on this particular multi-component formula, which differentiates it from single-component drugs or supplements.

Q: What happens if I miss a scheduled dose of Hemo 15?

Official drug labels are required to contain a protocol for managing missed doses. The label for Hemo 15 for the approved species provides a specific, non-advisory description of the action to take, in accordance with the prescribed treatment schedule.

Q: Are there any known interactions between Hemo 15 and over-the-counter pain relievers?

The official drug-drug interaction sections in the veterinary monograph detail known prohibitions and precautions. While an official label may not list every specific over-the-counter pain reliever, it establishes the authoritative basis for known component interactions within the approved species.

Q: Can Hemo 15 interact with antacids or heartburn medicines?

Official regulatory information must provide details on interactions between its components (such as Iron) and certain classes of medicines that affect absorption or metabolism. This information establishes necessary precautions for the approved animal species.

Q: How does the way Hemo 15 works compare to similar treatments?

Official regulatory texts describe Hemo 15 as an injectable form categorized as a hematinic and general reconstituent agent. This pharmacological and administration classification is the basis by which it is formally differentiated from other treatments in the same therapeutic class.

How should Hemo 15 be stored and disposed of?

How to Store and Dispose of Hemo 15

The storage and disposal of Hemo 15 (solution for injection) must adhere strictly to the official requirements detailed in its regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store between 15 C and 25 C.
Protection	The product must be protected from freezing and stored in its original container.
Child Safety	Keep out of the sight and reach of children.

Stability and Disposal

The multi-dose vial has a limited in-use stability period. Once the container has been opened for the first time, any unused product must be discarded after 28 days.

Disposal of unused or expired product and related waste materials must be carried out in accordance with local and national regulations. The solution must not be poured into wastewater or discarded with regular household trash.

Hemo 15